Clinical Trial Update: Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating everolimus in combination with imatinib in gastrointestinal stromal tumors refractory or resistant to imatinib has completed; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Everolimus (everolimus)
• Imatinib (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-25